May 11, 2025

Who Stops GA Therapy—and Why

By Jim Gallagher, senior managing editor

May 11, 2025

A Shift in Strategy for Ocular Melanoma

By Timothy G. Murray, MD, MBA, FACS

May 11, 2025

A Suprachoroidal Route to Retinal Therapy

By Jim Gallagher, senior managing editor

May 11, 2025

Migaldendranib May Move the Needle in AMD, DME

By Michael A. Singer, MD

May 11, 2025

New Hope for Stargardt Patients

By Jim Gallagher, senior managing editor

May 10, 2025

Reducing the Risk of Radiation Retinopathy

By Jim Gallagher, senior managing editor

May 10, 2025

AI Tools Can Help Low-Vision Patients

By Mitul Mehta, MD, MS, FASRS

May 10, 2025

Real-World nAMD Treatment Patterns Reveal Cost of Switching

By Jim Gallagher, senior managing editor

May 10, 2025

EYP-1901 Shows Durable, Sustained Efficacy in VERONA

By Carl D. Regillo, MD, FACS

May 10, 2025

Efficacy Data on Eye Drop for DME Presented at RWC

By Jim Gallagher, senior managing editor

May 9, 2025

FDA Shares Insights on Treatment Approvals, Clinical Trial Design

By Jim Gallagher, senior managing editor

May 9, 2025

Pooled Data on NT-501 Presented at RWC

By W. Lloyd Clark, MD

May 9, 2025

Fas Inhibition Shows Neuroprotective Benefit for GA

By Jim Gallagher, senior managing editor

May 9, 2025

PRISM Trial Update Presented at RWC

By Mark R. Barakat, MD

May 9, 2025

Current Pipeline for Noninfectious Uveitis

By Jim Gallagher, senior managing editor